You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
|
|---|---|
| Published in |
Advances in Therapy, December 2016
|
| DOI | 10.1007/s12325-016-0461-z |
| Pubmed ID | |
| Authors |
Vanessa Andrés-Guerrero, Lucía Perucho-González, Julián García-Feijoo, Laura Morales-Fernández, Federico Saenz-Francés, Rocío Herrero-Vanrell, Luis Pablo Júlvez, Vicente Polo Llorens, José María Martínez-de-la-Casa, Anastasios-Georgios P. Konstas |
| Abstract |
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has demonstrated the utility of these therapies for the treatment of other ocular conditions characterized by elevated VEGF levels. In this article we review current perspectives on the use of anti-VEGF drugs as adjuvant therapy in the management of neovascular glaucoma (NVG). The use of anti-VEGFs for modifying wound healing in glaucoma filtration surgery (GFS) is also reviewed. Selected studies investigating the use of anti-VEGF agents or antimetabolites in GFS or the management of NVG have demonstrated that these agents can improve surgical outcomes. However, anti-VEGF agents have yet to demonstrate specific advantages over the more established agents commonly used today. Further studies are needed to evaluate the duration of action, dosing intervals, and toxicity profile of these treatments. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 75 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 16% |
| Other | 11 | 15% |
| Student > Bachelor | 6 | 8% |
| Researcher | 6 | 8% |
| Student > Postgraduate | 5 | 7% |
| Other | 14 | 19% |
| Unknown | 21 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 41% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Agricultural and Biological Sciences | 2 | 3% |
| Engineering | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 26 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2018.
All research outputs
#6,996,768
of 22,925,760 outputs
Outputs from Advances in Therapy
#628
of 2,366 outputs
Outputs of similar age
#129,864
of 420,829 outputs
Outputs of similar age from Advances in Therapy
#15
of 40 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,366 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,829 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.